Targeting the mevalonate pathway sensitizes multiple myeloma cells to bortezomib through induction of mitochondrial metabolic disruption
{{output}}
Background: Multiple myeloma (MM) remains an incurable hematologic malignancy with bortezomib resistance representing a major therapeutic challenge. The mevalonate (MVA) pathway, a crucial metabolic cascade involved in cholestero... ...
